bioAffinity Technologies (BIAF) Free Cash Flow (2021 - 2026)

bioAffinity Technologies (BIAF) has reported Free Cash Flow for 6 consecutive years, with -$3.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow fell 91.01% year-over-year to -$3.2 million; the TTM figure through Mar 2026 stood at -$10.9 million (down 64.38% YoY), while the FY2025 annual figure was -$9.4 million, down 27.85% from the prior year.
• Free Cash Flow slipped to -$3.2 million in Q1 2026 per BIAF's latest filing, from -$2.6 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$376141.0 in Q2 2022 and bottomed at -$3.2 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$1.8 million across 5 years, with a median of -$1.7 million in 2024.
• Annual changes were most pronounced in 2023 — Free Cash Flow slumped 262.58% — and 2025, when it climbed 29.1%.
• bioAffinity Technologies' Free Cash Flow stood at -$1.3 million in 2022, then slipped by 23.24% to -$1.6 million in 2023, then fell by 4.64% to -$1.7 million in 2024, then sank by 52.61% to -$2.6 million in 2025, then dropped by 26.31% to -$3.2 million in 2026.
• Business Quant data shows BIAF's Free Cash Flow at -$3.2 million in Q1 2026, -$2.6 million in Q4 2025, and -$2.5 million in Q3 2025.